Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 618 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR After a Generous Donor Covered Her Bills, Breast Cancer Survivor Raises... December 22, 2020 EMA Recommends Granting a Marketing Authorisation for Generic Abiraterone for the... March 8, 2021 Off Target: Investigating the Abscopal Effect as a Treatment for Cancer January 28, 2020 Utility of a Methylation-Based Multicancer Early Detection Test in Identifying Whom... July 4, 2023 Load more HOT NEWS EMA Recommends Extension of Indications for Idecabtagene Vicleucel Trial Results Support SBRT as a Standard Option for Some Prostate... New Cancer Diagnoses Jump at Age 65, Suggesting People Put Off... Drug Regimen Boosts Survival of People with Advanced Colorectal Cancer
